Monte Rosa Therapeutics I... (GLUE)
undefined
undefined%
At close: undefined
7.60
0.86%
After-hours Dec 13, 2024, 06:37 PM EST

Cashflow (Annual)

Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
Year FY23 FY22 FY21 FY20 FY19
Net Income -135.35M -108.50M -73.96M -35.88M -7.74M
Depreciation & Amortization 6.22M 3.75M 2.13M 537.00K 72.00K
Stock-Based Compensation 16.67M 11.66M 5.20M 354.00K -
Other Working Capital 64.81M -1.39M 6.99M 820.00K -1.09M
Other Non-Cash Items -3.81M 2.76M 960.00K 7.68M -276.00K
Deferred Income Tax - - 17.00K - -
Change in Working Capital 72.47M -2.13M 6.29M 4.25M 1.77M
Operating Cash Flow -43.80M -92.47M -59.36M -23.05M -6.17M
Capital Expenditures -19.04M -12.91M -9.73M -3.39M -1.39M
Acquisitions - 109.00K 79.00K - -
Purchase of Investments -103.15M -384.42M - - -
Sales Maturities Of Investments 210.93M 178.00M - - -
Other Investing Acitivies 62.00K -206.31K 79.00 - -
Investing Cash Flow 88.80M -219.22M -9.65M -3.39M -1.39M
Debt Repayment - - - - 750.00K
Common Stock Repurchased - - - -440.00K -
Dividend Paid - - - - -
Other Financial Acitivies 27.49M 411.00K 139.81M 60.50M 14.25M
Financial Cash Flow 27.49M 20.47M 377.56M 60.06M 15.00M
Net Cash Flow 72.49M -291.22M 308.55M 33.62M 7.44M
Free Cash Flow -62.84M -105.38M -69.09M -26.44M -7.56M